AR108101A1 - Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 - Google Patents
Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119Info
- Publication number
- AR108101A1 AR108101A1 ARP170100901A ARP170100901A AR108101A1 AR 108101 A1 AR108101 A1 AR 108101A1 AR P170100901 A ARP170100901 A AR P170100901A AR P170100901 A ARP170100901 A AR P170100901A AR 108101 A1 AR108101 A1 AR 108101A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- gpr119
- formula
- affections
- treat diseases
- Prior art date
Links
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical class CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 title 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 title 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229940100607 GPR119 agonist Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) como agonistas de GPR119, composiciones que contienen dichos compuestos y método de preparación de las mismas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde, X¹, X², X³ y X⁴ son cada uno independientemente N, O, S o CH; Y se selecciona a partir de H, OH, halógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, -(CH)ₙ, amino,-CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -OCH(CH₃); n es 0, 1, 2 ó 3; ⁻ ⁻ ⁻ ⁻ ⁻ es independientemente ya sea un enlace simple o un enlace doble, siempre que enlaces dobles adyacentes (=C=) no estén permitidos; R¹ se selecciona a partir de los restos del grupo de fórmulas (2); R² se selecciona a partir de los restos del grupo de fórmulas (3); R³ se selecciona a partir de H, OH, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, -(CH)ₙ, amino, -CO, -CONH, -NH(alquilo), -N(alquilo)₂, -NH-aralquilo, -CF₃, -OCH(CH₃), un resto de fórmula (4), un resto de fórmula (5); y sales, hidratos y estereoisómeros farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611012425 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108101A1 true AR108101A1 (es) | 2018-07-18 |
Family
ID=58794109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100901A AR108101A1 (es) | 2016-04-08 | 2017-04-07 | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10526345B2 (es) |
| EP (1) | EP3440087B1 (es) |
| JP (1) | JP6831450B2 (es) |
| CN (1) | CN109415381B (es) |
| AR (1) | AR108101A1 (es) |
| AU (2) | AU2017246996B2 (es) |
| CA (1) | CA3020478C (es) |
| ES (1) | ES2926625T3 (es) |
| MX (1) | MX388682B (es) |
| NZ (2) | NZ763098A (es) |
| RU (1) | RU2749111C2 (es) |
| TW (1) | TWI657091B (es) |
| WO (1) | WO2017175068A1 (es) |
| ZA (1) | ZA201807350B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| US10208030B2 (en) * | 2016-04-08 | 2019-02-19 | Mankind Pharma Ltd. | GPR119 agonist compounds |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| KR20210123337A (ko) * | 2019-01-31 | 2021-10-13 | 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 | 방향족 고리 또는 헤테로방향족 고리 화합물, 이의 제조 방법 및 이의 의학 용도 |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021222366A1 (en) * | 2020-04-28 | 2021-11-04 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| WO2023009712A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy thiazolo azines as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| IL291418B2 (en) | 2022-03-16 | 2024-05-01 | Anima Biotech Inc | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| US12102693B1 (en) | 2023-08-25 | 2024-10-01 | Nanomedtrix, Llc | Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1340697A (en) * | 1920-02-24 | 1920-05-18 | Austin Herbert | Road-wheel of the sheet-metal type |
| NZ225967A (en) | 1987-09-02 | 1992-03-26 | Smithkline Beckman Corp | Substituted pyrrolo(1,2-a)imidazole and pyrrolo(1,2-a)pyridine derivatives; pharmaceutical compositions; intermediates |
| EP0799216A1 (en) | 1994-12-21 | 1997-10-08 | The Dow Chemical Company | Substituted thiadiazoles, compositions containing them and their use as antimicrobial and marine antifouling agents |
| AU2009231906A1 (en) | 2008-03-31 | 2009-10-08 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| US20110160222A1 (en) | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
| UY33805A (es) * | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| EA201300846A1 (ru) | 2011-01-21 | 2013-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Конденсированные дигидрофураны в качестве модуляторов gpr119, предназначенные для лечения диабета, ожирения и родственных нарушений |
| SG192941A1 (en) * | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CA2836487A1 (en) * | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| CN102898400B (zh) | 2011-07-28 | 2015-04-29 | 北京韩美药品有限公司 | Gpr119激动剂及其应用 |
| US8853239B2 (en) * | 2011-12-09 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| DK2858986T3 (da) | 2012-06-12 | 2019-11-25 | Chong Kun Dang Pharmaceutical Corp | Piperidinderivater som gpr119-agonister |
-
2017
- 2017-04-04 US US15/478,883 patent/US10526345B2/en active Active
- 2017-04-05 RU RU2018138050A patent/RU2749111C2/ru active
- 2017-04-05 MX MX2018012087A patent/MX388682B/es unknown
- 2017-04-05 ES ES17726352T patent/ES2926625T3/es active Active
- 2017-04-05 CN CN201780022556.2A patent/CN109415381B/zh active Active
- 2017-04-05 JP JP2019503800A patent/JP6831450B2/ja active Active
- 2017-04-05 NZ NZ763098A patent/NZ763098A/en unknown
- 2017-04-05 CA CA3020478A patent/CA3020478C/en active Active
- 2017-04-05 WO PCT/IB2017/000471 patent/WO2017175068A1/en not_active Ceased
- 2017-04-05 EP EP17726352.2A patent/EP3440087B1/en active Active
- 2017-04-05 NZ NZ746954A patent/NZ746954A/en unknown
- 2017-04-05 AU AU2017246996A patent/AU2017246996B2/en active Active
- 2017-04-07 TW TW106111799A patent/TWI657091B/zh active
- 2017-04-07 AR ARP170100901A patent/AR108101A1/es active IP Right Grant
-
2018
- 2018-11-02 ZA ZA2018/07350A patent/ZA201807350B/en unknown
-
2019
- 2019-10-14 US US16/601,109 patent/US10919915B2/en active Active
-
2020
- 2020-02-27 AU AU2020201450A patent/AU2020201450B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018138050A (ru) | 2020-05-12 |
| RU2018138050A3 (es) | 2020-05-12 |
| AU2020201450A1 (en) | 2020-03-19 |
| CN109415381B (zh) | 2022-03-25 |
| TW201741318A (zh) | 2017-12-01 |
| RU2749111C2 (ru) | 2021-06-04 |
| WO2017175068A8 (en) | 2018-05-11 |
| MX388682B (es) | 2025-03-20 |
| ZA201807350B (en) | 2019-08-28 |
| JP6831450B2 (ja) | 2021-02-17 |
| US10919915B2 (en) | 2021-02-16 |
| AU2017246996A1 (en) | 2018-11-01 |
| CA3020478C (en) | 2021-07-20 |
| MX2018012087A (es) | 2019-06-12 |
| TWI657091B (zh) | 2019-04-21 |
| NZ746954A (en) | 2020-04-24 |
| EP3440087A1 (en) | 2019-02-13 |
| AU2020201450B2 (en) | 2021-07-01 |
| CN109415381A (zh) | 2019-03-01 |
| CA3020478A1 (en) | 2017-10-12 |
| JP2019513834A (ja) | 2019-05-30 |
| AU2017246996B2 (en) | 2019-11-28 |
| ES2926625T3 (es) | 2022-10-27 |
| WO2017175068A1 (en) | 2017-10-12 |
| US10526345B2 (en) | 2020-01-07 |
| NZ763098A (en) | 2023-04-28 |
| US20170291910A1 (en) | 2017-10-12 |
| US20200040006A1 (en) | 2020-02-06 |
| EP3440087B1 (en) | 2022-08-10 |
| BR112018070727A2 (pt) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108101A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR108102A1 (es) | Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119 | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| CL2021001098A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2020000404A (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
| UY36207A (es) | Inhibidores de la syk | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| ECSP088257A (es) | Derivados de amida | |
| AR120578A1 (es) | DERIVADOS DE BENCILAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 (TGFbRI) / ALK5 | |
| AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
| PE20140629A1 (es) | Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos | |
| AR071111A1 (es) | Derivados de amidas del acido 3-trifluorometil-pirazin-2-carboxilico como agentes para aumentar el hdl-colesterol, composiciones farmaceuticas y un metodo para su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |